By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BIND Therapeutics 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-491-3400 Fax: 617-491-0351


Company News
BIND Therapeutics (BIND) Release: AZD2811 ACCURINS Data Published In Science Translational Medicine Highlight One Of The First Applications Of Nanomedicine To Molecularly Targeted Cancer Therapies 2/11/2016 9:43:38 AM
BIND Therapeutics (BIND) Provides Enrollment Update For Phase II Insite 1 And Insite 2 Trials With BIND-014 1/27/2016 8:50:20 AM
BIND Therapeutics (BIND) Complete Data On Clinical Activity Of BIND-014 In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) At The 2016 Genitourinary Cancers Symposium 1/7/2016 11:07:51 AM
BIND Therapeutics (BIND) To Present At Biotech Showcase 2016 1/5/2016 11:00:25 AM
BIND Therapeutics (BIND) Appoints Jonathan Yingling, Ph.D., As Chief Scientific Officer 12/16/2015 10:31:44 AM
BIND Therapeutics (BIND) To Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort To Second Stage Of iNSITE 1 Trial 12/14/2015 1:01:24 PM
BIND Therapeutics (BIND) Announces Initiation Of Clinical Studies With Accurin AZD2811 In Solid Tumors 11/18/2015 7:55:21 AM
BIND Therapeutics (BIND) To Present At 2015 Stifel Healthcare Conference 11/10/2015 11:31:44 AM
BIND Therapeutics (BIND) Presents Data Demonstrating Ability Of Accurins To Improve Efficacy And Tolerability Of Multiple Anti-Cancer Agents 11/9/2015 2:12:58 PM
BIND Therapeutics (BIND) Reports Third Quarter 2015 Financial Results And Provides Corporate Update 11/2/2015 9:41:16 AM